VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $1.476 million which beat the analyst consensus estimate of $250.000 thousand by 490.40 percent. This is a 504.92 percent increase over sales of $244.000 thousand the same period last year.